Emerging Drugs for Hypogonadism

Male hypogonadism, a common endocrine issue, saw increased testosterone use among middle-aged and older men, even those with borderline or normal levels. Advances in treatments led to the replacement of old injectable testosterone esters with transdermal formulations and long-acting injectables like testosterone undecanoate. Pharmaceutical data indicated a market shift towards more expensive but easier-to-administer transdermal therapies that provide physiological testosterone levels. Emerging treatments included selective androgen receptor modulators (SARMs), 7α-methyl-19-nortestosterone, aromatase inhibitors, clomifene, dihydrotestosterone, and human chorionic gonadotropin, with SARMs aiming to target specific tissues to reduce prostate-related side effects.